Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome to the real world.
More like $3. As usual with this stock.
Market closed tomorrow lol
Hey guys, Nob here! I hope all is well with you folks :) Woke up after a long AVXL wintersleep and see we are finally mooning again. What's the news?
Did good 'ol Bill get the memo about Anavex yet?
While we wait in silence....maybe this is a good book to read:
The Billion-Dollar Molecule. One Company's Quest for the Perfect Drug By Barry Werth
http://www.nytimes.com/1994/02/10/books/books-of-the-times-trying-to-invent-a-drug-and-not-just-find-it.html
True story about a young, promising but struggling biotech trying to make it to the top. Wall Street's ignorance was appaling there too.
https://www.xconomy.com/boston/2010/08/04/how-eli-lilly-let-a-billion-dollar-molecule-slip-away-and-make-a-fortune-for-vertex/
And remember; 'science is tricky', right ffrol? :)
UH OH..new PR
“Mental health is an issue our nation must address, and the best way to do that is to continue to work together from all sides and educate our policy leaders,” said E. Teresa Touey, organizer of the MHPAEA Business Roundtable. “It is important for panelists such as Dr. Missling to attend in order to lend his expertise in developing therapies for diseases such as Alzheimer’s disease as well as other neurological disorders with high unmet needs.”
Hey, 'only' 6 strong responders represent 25% of the Alzheimer's population (on non-optimized doses). The other 75% are not doing as bad as you want to make people believe. It is just not the group being focussed on for the Phase 2/3 trial design. Cure the mild Alzheimer's sufferers and there won't be any moderate to severe sufferer left in a few years from now.
See the bigger picture.
So Anavex's A2-73 data has shown everyone willing to see that it's:
- safe
- tolerable
- dose dependent (yet to be optimized!)
- able to increase MMSE, ADCS-ADL scores (rare events)
- maintaining its therapeutic effect (no wear-off)
- representative for a larger population (hello Phase 2/3)
- a possible ALZ prevention medicine (the younger the better)
No matter how hard the naysayers try to spin/downplay/ignore the stunning 2 year data, the highlighted 6 strong responders (out of 24 patients who all seem to have benefitted, just not as much) are a testament of what was once thought impossible. Well done Anavex!
So this is basically an Ariana presentation, not an Anavex presentation. That explains why this event is not mentioned on Anavex's website.
Talking about webcast, will Anavex's presentation be webcasted tomorrow?
Would like to hear about his 'experts' too. Adam Feuerstein does not count.
Wall Street is trickiest. Full of sharks and thieves.
I agree, AXON's failure and drop was predictable. AVXL getting dragged down with it is a buying opportunity for those who have some dry powder left.
Dr. Missling was invited two times to the Washington DC U.S. Capitol roundtable, remember?
http://www.anavex.com/anavex-to-present-at-third-annual-mhpaea-business-roundtable-in-washington-d-c/
http://www.anavex.com/anavex-life-sciences-to-present-at-annual-mental-health-parity-addiction-equity-act-roundtable-at-u-s-capitol-washington-dc/
Now, why would they invite the CEO of a tiny biotech to Washington DC where all the policies are made? Makes you go hmmmm.
I remember we used to chuckle about Missling being the one invited there and not some hot-shot Big Pharma CEO.
He must be in 'Heaven'.. :)
The cat saw it.
More positive press for Anavex
http://www.microcapdaily.com/the-compelling-story-of-anavex-life-sciences-corp-nasdaqavxl/120026/
Nice article on Business Insider with Anavex mention:
http://markets.businessinsider.com/news/stocks/Alzheimer-s-Disease-Cannabis-Formulation-Shows-Promise-1002361935
Neal Sharpe, Senior Director of Preclinical Safety and Operations has left Anavex two days ago to become Senior Director of Toxicology at Eloxx Pharmaceuticals.
Maybe he got bored at Anavex. Not much to do when a drug is safe and non-toxic.
http://markets.businessinsider.com/news/stocks/Eloxx-Pharmaceuticals-Expands-Management-Team-to-Support-Rapid-Development-of-Lead-Drug-Candidate-ELX-02-for-the-Treatment-of-Rare-Genetic-Diseases-1002353442
I think you forgot about this conference
http://www.meetmax.com/sched/event_43291/~public/conference_companies.html?event_id=43291&bank_access=0
New Insider Financial article on Anavex:
https://insiderfinancial.com/we-called-the-anavex-life-sciences-corp-nasdaqavxl-bounce-whats-next
The article of your link is from November 2013.
The 10Q from August 2015 states;
'In a humanized calibrated cortical network computer model the unexpected pre-clinical synergy between ANAVEX 2-73 and donepezil was confirmed and ANAVEX PLUS showed an anticipated ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks, which represents more than 2x the ADAS-Cog of donepezil alone.'
Also, the positive synergy claim is still on Anavex's website so we can assume that they stand by their conclusion. If there was no synergy, why keep it on the site?
Some people seem to have a hard time accepting statements from a small biotech company and doubt everything when it comes to scientific progress, no matter how many facts you throw at them.
The same goes for financing;
“We are entering the second half of 2017 with our strongest balance sheet to date, which allows the Company to execute the Phase 2 clinical trial in Rett syndrome, for which ANAVEX™ 2-73 has been granted Orphan Drug Designation by the FDA, as well as the Phase 2/3 clinical trial in Alzheimer’s disease and the Phase 2 clinical trial in Parkinson’s disease.”.
There are naysayers who believe that Anavex doesn't even have enough funding to bring the Alzheimer's trial to an end with the current cash at hand. Well, read again.
I'm not saying small biotechs haven't mislead investors in the past but Anavex looks pretty damn serious. As always, do your own due diligence and invest only what you can afford to lose.
I'm not dreaming because I know those days are gonna come sooner than later.
If these poor girls can get rid of their prolonged or repeated seizures by taking A2-73, I think we are golden already.
I-agree-Reyeton.--Those-on-the-sidelines-are-running-the-risk-of-missing-out-on-a-big-run.--Trying-to-scrape-the-bottom-of-the-barrel-and-hoping-for-another-big-drop-is-not-the-best-idea.-- A-PR-tomorrow-can-change-everything.
Maybe Missling will surprise us on September 26th at the Ladenburg Thalmann 2017 Healthcare Conference?
http://www.meetmax.com/sched/event_43291/~public/conference_companies.html?event_id=43291&bank_access=0
Why is there no % change and why is the 'previous shares' tab empty for Vanguard? Odd.